Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 11/20 | 0.49 |
| ▸ | PTGS1 | P23219 | 6/20 | 0.49 |
| ▸ | PTGES2 | Q9H7Z7 | 2/20 | 0.44 |
| ▸ | ACLY | P53396 | 2/20 | 0.39 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.39 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.39 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.39 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.39 |
| ▸ | XDH | P47989 | 1/20 | 0.38 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.38 |
| ▸ | PTGER1 | P34995 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6718641 | 0.89 | PTGS2 (0.56) | PTGS2PTGS1PTGES2 | |
| SCHEMBL7048690 | 0.88 | PTGS2 (0.50) | PTGS2PTGS1ACLYGABRG2GABRB3 | |
| SCHEMBL6728016 | 0.87 | PTGER1 (0.44) | PTGS2PTGS1PTGES2ACLYGABRG2 | |
| SCHEMBL6728824 | 0.86 | PTGS2 (0.47) | PTGS2PTGS1PTGES2ACLYGABRG2 | |
| SCHEMBL6718766 | 0.83 | PTGS2 (0.55) | PTGS2PTGS1 | |
| SCHEMBL6730086 | 0.83 | PTGS2 (0.61) | PTGS2PTGS1 | |
| SCHEMBL6723561 | 0.83 | PTGS2 (0.46) | PTGS2PTGS1PTGES2 | |
| SCHEMBL6725449 | 0.81 | PTGS2 (0.52) | PTGS2PTGS1 | |
| SCHEMBL6719083 | 0.81 | PTGS2 (0.56) | PTGS2PTGS1 | |
| SCHEMBL6721428 | 0.81 | PTGS2 (0.52) | PTGS2PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040092552-A1 | 2-Fluorobenzenesulfonyl compounds for the treatment of inflammation | PHARMACIA CORPORATION | 2004-05-13 | — | — | US | disclosed |
| EP-1296971-A2 | 2-FLUOROBENZENESULFONYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION | Pharmacia Corporation (US) | 2003-04-02 | — | — | EP | disclosed |
| WO-2001081332-A2 | 2-FLUOROBENZENESULFONYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION | PHARMACIA CORPORATION (US) | 2001-11-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040092552-A1 | 2-Fluorobenzenesulfonyl compounds for the treatment of inflammation | FPR2, PTGES2, FPR1 | PTGS2 5/4885PTGS1 4/4885PTGES2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.